Barclays
CYTO

Barclays’s Altamira Therapeutics Ltd CYTO Stock Holding History

Barclays’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Hold
0
– – – 5375
2022
Q1 		– Hold
0
– – – 5766
2019
Q2 		– Hold
0
– – – 7385
2019
Q1 		– Sell
-1
Closed -$3.21K – 7428
2018
Q4 		$5K Buy
+1
New +$5.11K ﹤0.01% 6470

Other funds holding CYTO

Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Barclays's CYTO Position: Q2 2022 in Review

Barclays held its Altamira Therapeutics Ltd (CYTO) position steady in Q2 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5375.

Barclays first reported a position in CYTO in Q4 2018 and has held it in 1 quarter since. The position peaked at $5K in Q4 2018. 12 funds tracked by Wall St. Rank hold CYTO as of Q2 2022.

  • Barclays held 0 shares of Altamira Therapeutics Ltd worth $0 as of Q2 2022.
  • Barclays left its Altamira Therapeutics Ltd share count unchanged in Q2 2022.
  • Altamira Therapeutics Ltd made up ﹤0.01% of Barclays's portfolio in Q2 2022, its #5375 holding.
  • Barclays first reported a position in Altamira Therapeutics Ltd in Q4 2018 and has held it in 1 quarter since.
  • Barclays's Altamira Therapeutics Ltd position peaked at $5K in Q4 2018.
  • 12 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.